In a move to attract investors, Fibrocell Science, Inc. of Exton is transferring its U.S. stock exchange listing from the New York Stock Exchange to the NASDAQ Capital Market.

The autologous cell therapy company is focused on developing first-in class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs.

The company said Aug. 18 it expects its securities to cease trading on the NYSE at the close of business Aug. 28, and to commence trading on NASDAQ on Aug. 29 when the market opens. Fibrocell will retain its current ticker symbol, “FCSC,” when trading begins on NASDAQ.

“We believe our move to NASDAQ will improve the visibility of our stock, enhance trading liquidity in our shares, and provide us with greater exposure to institutional investors,” said Gregory Weaver, senior vice president and chief financial officer.

Currently, Fibrocell’s lead orphan drug program is in late-stage pre-clinical development for the treatment of RDEB (recessive dystrophic epidermolysis bullosa). Working in collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology, Fibrocell is genetically modifying autologous fibroblast cells to express target proteins that are inactive or missing from patients with rare genetic skin and tissue disorders. Fibrocell is also pursuing medical applications for azficel-T, its proprietary autologous fibroblast technology, for restrictive burn scarring and vocal cord scarring. Both are currently in Phase II clinical trials.